Having trouble accessing articles? Reset your cache.

Confirming CRISPR

Questions about CRISPR gene editing in human embryos highlight need for assays

Two critiques of a 2017 human embryo gene editing study, including one suggesting large deletions at the target site misled researchers into thinking CRISPR-Cas9 corrected a genetic mutation, raise questions about what assays and screening methods are needed to characterize on- and off-target edits.

In a paper published in Nature last year, a team led by Oregon Health & Science University researchers suggested they used CRISPR-Cas 9 editing to correct a mutation in the myosin binding protein C cardiac (MYBPC3) gene in human embryos. The team used embryos created from healthy donor eggs from 12 women and sperm from one hypertrophic cardiomyopathy

Read the full 1019 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers